Fujii, Masanori <br/><br/>
Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure.  [electronic resource] 

 -  Journal of cardiovascular pharmacology  Nov 2004 
 - S346-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4023 
<br/><br/><label>Standard No.: </label>10.1097/01.fjc.0000166265.09550.7c  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aldosterone--blood<br/>Angiotensin-Converting Enzyme Inhibitors--pharmacology<br/>Animals<br/>Bradykinin--metabolism<br/>Bradykinin B2 Receptor Antagonists<br/>Collagen--genetics<br/>Disease Models, Animal<br/>Dogs<br/>Enalapril--pharmacology<br/>Endothelin-1--genetics<br/>Fibrosis<br/>Heart Failure--drug therapy<br/>Hemodynamics--drug effects<br/>Myocardium--enzymology<br/>Nitric Oxide--metabolism<br/>Nitric Oxide Synthase Type II--metabolism<br/>Nitric Oxide Synthase Type III<br/>Quinolines--pharmacology<br/>RNA, Messenger--metabolism<br/>Receptor, Bradykinin B2--metabolism<br/>Renin--blood